
Please try another search
By Maggie Fick
LONDON (Reuters) -AstraZeneca appeared to play down speculation about the future of its CEO after its shares fell more than 4% on Monday following a British tabloid report that Pascal Soriot was considering leaving the drugmaker as soon as next year.
The company initially declined to comment on the Mail on Sunday report, but later issued a statement saying: "We do not comment on market rumours. We have regulatory obligations and were there any truth in a rumour that could significantly impact our share price we would make an announcement."
AstraZeneca (NASDAQ:AZN) shares closed down 3.2% after earlier touching their lowest since July 19.
Three analysts and one AstraZeneca shareholder told Reuters they attributed the move to the Mail on Sunday report that said Soriot had privately told friends and advisers he may leave the company as soon as next year.
Reuters could not independently verify the information.
Two of the analysts and the shareholder also said an article published on Monday in the Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report.
The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July. In it, Pangalos was quoted as saying: "Pascal has got a lot of years ahead of him and he works as hard and as intensely as he did when I first met him in 2012."
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.